Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled phase 3 study of oral dexpramipexole in severe eosinophilic asthma
CTR20244124Phase 3Terminated
- Sponsor
- Areteia Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexpramipexole in eosinophilic asthma (EA), sponsored by Areteia Therapeutics. Started Nov 2024; status: terminated.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20244124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244124.